Outlook TherapeuticsNASDAQ: OTLK

NEW YORK, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Outlook Therapeutics, Inc. (NASDAQ: OTLK) on behalf of long-term stockholders following a class action complaint that was filed against Outlook on November 3, 2023 with a Class Period from December 29, 2022 to August 29, 2023. Our investigation concerns whether the board of directors of Outlook have breached their fiduciary duties to the company.

Live video webcast with Russell Trenary, President and CEO of Outlook Therapeutics on Thursday, September 19th at 4:00 PM ET Live video webcast with Russell Trenary, President and CEO of Outlook Therapeutics on Thursday, September 19th at 4:00 PM ET

ISELIN, N.J., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that has achieved regulatory approval in the EU and UK for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), today announced financial results for the third quarter of fiscal year 2024 and provided a corporate update. As previously announced, Outlook Therapeutics will host its quarterly conference call and live audio webcast, today, Wednesday, August 14, 2024, at 8:30 AM ET (details below).

ISELIN, N.J., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg; bevacizumab gamma) for the treatment of retina diseases, today announced that Russell Trenary, President and CEO of Outlook Therapeutics will participate in a fireside chat at the H.C. Wainwright 4 th Annual Ophthalmology Virtual Conference being held on Thursday, August 15, 2024.

ISELIN, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that has achieved regulatory approval in the EU and UK for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet AMD, today announced that it will report its financial results for third quarter fiscal year 2024 on Wednesday, August 14, 2024. Outlook Therapeutics management will host its quarterly conference call and live audio webcast to discuss the operational and financial results at 8:30 AM ET that same day.

It's essential to remember that low-float biopharmaceutical companies often experience volatility due to frequent breaking news and technical factors such as float size and short interest. While the bullish price target is noteworthy, it's crucial to delve deeper into the company's fundamentals and recent developments to understand what analysts might be seeing or missing.

ISELIN, N.J., June 11, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the commercialization and development of ONS-5010/LYTENAVA™ (bevacizumab-vikg; bevacizumab gamma), for the treatment of retina diseases, today announced that it will present at the Virtual Investor Pitch Conference on June 18, 2024 at 12:00 PM ET.

Watch the "What This Means" video here Outlook CEO, Russ Trenary underscores that LYTENAVA™ (bevacizumab gamma) has become the first ophthalmic formulation of bevacizumab to receive European Commission Marketing Authorization for the treatment of wet AMD FRENCHTOWN, NJ / ACCESSWIRE / June 6, 2024 / JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today released a Virtual Investor "What This Means" segment featuring Outlook Therapeutics, Inc. (Nasdaq:OTLK), a biopharmaceutical company focused on the commercialization and development of ONS-5010/LYTENAVA™ (bevacizumab-vikg; bevacizumab gamma), for the treatment of retina diseases. As part of this "What This Means" segment, Russell Trenary, President and Chief Executive Officer of Outlook Therapeutics, discusses the Company's recently received European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) for the treatment of wet AMD.

Outlook Therapeutics, Inc. (NASDAQ:OTLK) Q2 2024 Earnings Conference Call is scheduled for May 16, 2024 at 8:30 AM ET. Present on the call are Jenene Thomas from JTC Team, LLC, Russell Trenary - President & CEO, and Lawrence Kenyon - CFO. Also in attendance are conference call participants Julian Harrison from BTIG, Eddie Hickman from Guggenheim Securities, Douglas Tsao from HC Wainwright, Timothy Chiang from Capital One, Kemp Dolliver from Brookline Capital Markets, Ed Woo from Ascendiant Capital Markets, and Daniil Gataulin from Chardan. The operator welcomes everyone to the Outlook Therapeutics Inaugural Quarterly Update Conference Call and Webcast, reminding all participants that they are currently in listen-only mode.